Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients

Autor: Augusto César Penalva de Oliveira, Lenira Moraes, Luiz Henrique da Silva Nali, Dagoberto Callegaro, Camila Malta Romano, Maria Cristina Domingues da Silva Fink

Publikováno v: Arquivos de Neuro-Psiquiatria, Vol 72, Iss 12, Pp 960-965 (2014)
Arquivos de Neuro-Psiquiatria v.72 n.12 2014
Arquivos de neuro-psiquiatria
Academia Brasileira de Neurologia
instacron:ABNEURO
Arquivos de Neuro-Psiquiatria, Volume: 72, Issue: 12, Pages: 960-965, Published: 02 DEC 2014

Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis who have failed traditional prior therapies. However, prolonged use, prior immunosuppressive therapy and anti-JCV antibody status have been associated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc54ce6a28d58e1f6c904f7e77a00419
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2014001200960&lng=en&tlng=en

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.